Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.

Sir Marc Feldmann smiling

Sir Marc Feldmann, Emeritus Professor at the Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences has been awarded the 2020 Tang Prize in Biopharmaceutical Science. He was announced as joint winner alongside Charles Dinarello (US), and Tadamitsu Kishimoto (Japan) "for the development of cytokine-targeting biological therapies for treatment of inflammatory diseases."

Dr Feldmann received the award for his research into the molecular mechanisms of auto-immune inflammatory diseases. This revealed that tumor necrosis factor (TNF), a protein which regulates immune and inflammatory cells was a good therapeutic target in rheumatoid arthritis. This discovery led to the development of an anti-TNF antibody that Feldmann, and his clinical research colleague Maini, proved to be very effective against rheumatoid arthritis and has since enabled millions of patients to regain control of their lives. Anti-TNF was also shown to be effective in inflammatory bowel disease, psoriasis and ten other conditions. It was the first antibody therapy of a common disease, is the world's best-selling drug class, and facilitated the widespread uptake of antibody therapy by the pharmaceutical industry.

The full story is available on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.